Copyright © 2008 Peter Klein Klouwenberg and Louis Bont. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. World Health Organization, “Maternal Health and Safe Motherhood Programme,” MSM96.7, 1996.
2. The WHO Young Infants Study Group, “Conclusions from the WHO multicenter study of serious infections in young infants,” Pediatric Infectious Disease Journal, vol. 18, no. 10, supplement, pp. S32–S34, 1999. View at Publisher · View at Google Scholar
3. D. Thomas-Rudolph, T. W. Du Clos, C. M. Snapper, and C. Mold, “C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to Fc$\gamma$R on dendritic cells,” The Journal of Immunology, vol. 178, no. 11, pp. 7283–7291, 2007.
4. H. Jakobsen, S. Hannesdottir, S. P. Bjarnarson, et al., “Early life T Cell responses to pneumucoccal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy,” European Journal of Immunology, vol. 36, no. 2, pp. 287–295, 2006. View at Publisher · View at Google Scholar · View at PubMed
5. G. T. Rijkers, E. A. M. Sanders, M. A. Breukels, and B. J. M. Zegers, “Infant B cell responses to polysaccharide determinants,” Vaccine, vol. 16, no. 14-15, pp. 1396–1400, 1998. View at Publisher · View at Google Scholar
6. S. Bondada, H.-J. Wu, D. A. Robertson, and R. L. Chelvarajan, “Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines,” Vaccine, vol. 19, no. 4-5, pp. 557–565, 2000. View at Publisher · View at Google Scholar
7. D. E. Mosier, J. J. Mond, and E. A. Goldings, “The ontogeny of thymic independent antibody responses in vitro in normal mice and mice with an X-linked B cell defect,” The Journal of Immunology, vol. 119, no. 6, pp. 1874–1878, 1977.
8. J. J. Mond, A. Lees, and C. M. Snapper, “T cell-independent antigens type 2,” Annual Review of Immunology, vol. 13, no. 1, pp. 655–692, 1995. View at Publisher · View at Google Scholar · View at PubMed
9. J. J. Mond, Q. Vos, A. Lees, and C. M. Snapper, “T cell independent antigens,” Current Opinion in Immunology, vol. 7, no. 3, pp. 349–354, 1995. View at Publisher · View at Google Scholar
10. S. R. Yan, D. M. Byers, and R. Bortolussi, “Role of protein tyrosine kinase $\text{p}53/{56}^{lyn}$ in diminished lipopolysaccharide priming of formylmethionylleucyl- phenylalanine-induced superoxide production in human newborn neutrophils,” Infection and Immunity, vol. 72, no. 11, pp. 6455–6462, 2004. View at Publisher · View at Google Scholar · View at PubMed
11. O. Levy, R. B. Sisson, J. Kenyon, E. Eichenwald, A. B. Macone, and D. Goldmann, “Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo,” Infection and Immunity, vol. 68, no. 9, pp. 5120–5125, 2000. View at Publisher · View at Google Scholar
12. G. T. Rijkers, L. A. M. Sanders, and B. J. M. Zegers, “Anti-capsular polysaccharide antibody deficiency states,” Immunodeficiency, vol. 5, no. 1, pp. 1–21, 1993.
13. P. F. Wright and P. F. Wright, “Infectious diseases in early life in industrialized countries,” Vaccine, vol. 16, no. 14-15, pp. 1355–1359, 1998. View at Publisher · View at Google Scholar
14. J. Kovarik and C.-A. Siegrist, “Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators,” Immunology & Cell Biology, vol. 76, no. 3, pp. 222–236, 1998. View at Publisher · View at Google Scholar
15. M. Pihlgren, M. Friedli, C. Tougne, A.-F. Rochat, P.-H. Lambert, and C.-A. Siegrist, “Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival,” The Journal of Immunology, vol. 176, no. 1, pp. 165–172, 2006.
16. C. L. Trotter, N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay, “Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction,” The Lancet, vol. 364, no. 9431, pp. 365–367, 2004. View at Publisher · View at Google Scholar · View at PubMed
17. W. Timens, A. Boes, T. Rozeboom-Uiterwijk, and S. Poppema, “Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response,” The Journal of Immunology, vol. 143, no. 10, pp. 3200–3206, 1989.
18. B. J. M. Zegers, M. Van Der Giessen, E. E. Reerink-Brongers, and J. W. Stoop, “The serum IgG subclass levels in healthy infants of 13–62 weeks of age,” Clinica Chimica Acta, vol. 101, no. 2-3, pp. 265–269, 1980. View at Publisher · View at Google Scholar
19. N. Kutukculer, N. E. Karaca, O. Demircioglu, and G. Aksu, “Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency,” Pediatric Allergy and Immunology, vol. 18, no. 2, pp. 167–173, 2007. View at Publisher · View at Google Scholar · View at PubMed
20. D. J. Barrett and E. M. Ayoub, “IgG2 subclass restriction of antibody to pneumococcal polysaccharides,” Clinical and Experimental Immunology, vol. 63, no. 1, pp. 127–134, 1986.
21. E. Castagnola and F. Fioredda, “Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes,” European Journal of Haematology, vol. 71, no. 5, pp. 319–326, 2003. View at Publisher · View at Google Scholar
22. T. V. Adamkiewicz, B. J. Silk, J. Howgate, et al., “Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life,” Pediatrics, vol. 121, no. 3, pp. 562–569, 2008. View at Publisher · View at Google Scholar · View at PubMed
23. D. E. Mosier, I. M. Zitron, J. J. Mond, A. Ahmed, I. Scher, and W. E. Paul, “Surface immunoglobulin D as a functional receptor for a subclass of B lymphocytes,” Immunological Reviews, vol. 37, no. 1, pp. 89–104, 1977.
24. P. Balogh, Y. Aydar, J. G. Tew, and A. K. Szakal, “Ontogeny of the follicular dendritic cell phenotype and function in the postnatal murine spleen,” Cellular Immunology, vol. 214, no. 1, pp. 45–53, 2001. View at Publisher · View at Google Scholar · View at PubMed
25. A. Lanoue, M. R. Clatworthy, P. Smith, et al., “SIGN-R1 contributes to protection against lethal pneumococcal infection in mice,” Journal of Experimental Medicine, vol. 200, no. 11, pp. 1383–1393, 2004. View at Publisher · View at Google Scholar · View at PubMed
26. E. A. Koppel, M. Litjens, V. C. van den Berg, Y. van Kooyk, and T. B. H. Geijtenbeek, “Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses against Streptococcus pneumoniae,” Molecular Immunology, vol. 45, no. 10, pp. 2881–2887, 2008. View at Publisher · View at Google Scholar · View at PubMed
27. M.-J.P. Llopis, G. Harms, M. J. Hardonk, and W. Timens, “Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells,” Journal of Allergy and Clinical Immunology, vol. 97, no. 4, pp. 1015–1024, 1996. View at Publisher · View at Google Scholar
28. A. W. Griffioen, S. W. Franklin, B. J. M. Zegers, and G. T. Rijkers, “Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes,” Clinical Immunology and Immunopathology, vol. 69, no. 1, pp. 1–8, 1993. View at Publisher · View at Google Scholar
29. C. A. Davis, E. H. Vallota, and J. Forristal, “Serum complement levels in infancy: age related changes,” Pediatric Research, vol. 13, no. 9, pp. 1043–1046, 1979.
30. M. A. Breukels, A. Zandvoort, G. T. Rijkers, et al., “Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines,” Scandinavian Journal of Immunology, vol. 61, no. 4, pp. 322–328, 2005. View at Publisher · View at Google Scholar · View at PubMed
31. L. J. Kobrynski, A. O. Sousa, A. J. Nahmias, and F. K. Lee, “Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and ${\text{CD8}}^{+}$ cells,” The Journal of Immunology, vol. 174, no. 4, pp. 1787–1790, 2005.
32. R. L. Chelvarajan, N. L. Gilbert, and S. Bondada, “Neonatal murine B lymphocytes respond to polysaccharide antigens in the presence of IL-1 and IL-6,” The Journal of Immunology, vol. 161, no. 7, pp. 3315–3324, 1998.
33. D. F. Angelone, M. R. Wessels, M. Coughlin, et al., “Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-$\alpha$ production in vitro and in vivo,” Pediatric Research, vol. 60, no. 2, pp. 205–209, 2006. View at Publisher · View at Google Scholar · View at PubMed
34. R. L. Chelvarajan, S. M. Collins, I. E. Doubinskaia, et al., “Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens,” Journal of Leukocyte Biology, vol. 75, no. 6, pp. 982–994, 2004. View at Publisher · View at Google Scholar · View at PubMed
35. L. Chelvarajan, D. Popa, Y. Liu, T. V. Getchell, A. J. Stromberg, and S. Bondada, “Molecular mechanisms underlying anti-inflammatory phenotype of neonatal splenic macrophages,” Journal of Leukocyte Biology, vol. 82, no. 2, pp. 403–416, 2007. View at Publisher · View at Google Scholar · View at PubMed
36. G. J. Nossal, “Cellular mechanisms of immunologic tolerance,” Annual Review of Immunology, vol. 1, no. 1, pp. 33–62, 1983. View at Publisher · View at Google Scholar · View at PubMed
37. S. Kurikka, H. Käyhty, L. Saarinen, P.-R. Ronnberg, J. Eskola, and P. H. Makela, “Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy,” The Journal of Infectious Diseases, vol. 172, no. 5, pp. 1268–1272, 1995.
38. J. Eskola and H. Käyhty, “Early immunization with conjugate vaccines,” Vaccine, vol. 16, no. 14-15, pp. 1433–1438, 1998. View at Publisher · View at Google Scholar
39. J. Eskola, J. Ward, R. Dagan, D. Goldblatt, F. Zepp, and C.-A. Siegrist, “Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis,” The Lancet, vol. 354, no. 9195, pp. 2063–2068, 1999. View at Publisher · View at Google Scholar
40. B. Adkins, C. Leclerc, and S. Marshall-Clarke, “Neonatal adaptive immunity comes of age,” Nature Reviews Immunology, vol. 4, no. 7, pp. 553–564, 2004. View at Publisher · View at Google Scholar · View at PubMed
41. S. P. Bjarnarson, H. Jakobsen, G. Del Giudice, E. Trannoy, C.-A. Siegrist, and I. Jonsdottir, “The advantage of mucosal immunization for polysaccharide-specific memory responses in early life,” European Journal of Immunology, vol. 35, no. 4, pp. 1037–1045, 2005. View at Publisher · View at Google Scholar · View at PubMed
42. R. Booy, P. T. Heath, P. E. M. Slack, N. Begg, and E. R. Moxon, “Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster,” The Lancet, vol. 349, no. 9060, pp. 1197–1202, 1997. View at Publisher · View at Google Scholar
43. G. S. Ribeiro, J. B. T. Lima, J. N. Reis, et al., “Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil,” Vaccine, vol. 25, no. 22, pp. 4420–4428, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. M. L. Barbour, R. T. Mayon-White, C. Coles, D. W. M. Crook, and E. R. Moxon, “The impact of conjugate vaccine on carriage of Haemophilus influenzae type b,” The Journal of Infectious Diseases, vol. 171, no. 1, pp. 93–98, 1995.
45. P. H. Mäkelä, H. Peltola, H. Käyhty, et al., “Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland,” The Journal of Infectious Diseases, vol. 136, pp. S43–S50, 1977.
46. H. Peltola, “Meningococcal vaccines. Current status and future possibilities,” Drugs, vol. 55, no. 3, pp. 347–366, 1998.
47. L. O. Conterno, C. R. Silva Filho, J. U. Rüggeberg, and P. T. Heath, “Conjugate vaccines for preventing meningococcal C meningitis and septicaemia,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD001834, 2006. View at Publisher · View at Google Scholar · View at PubMed
48. A. Larrauri, R. Cano, M. García, and S. de Mateo, “Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain,” Vaccine, vol. 23, no. 32, pp. 4097–4100, 2005. View at Publisher · View at Google Scholar · View at PubMed
49. J. Findlow, S. Taylor, A. Aase, et al., “Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac,” Infection and Immunity, vol. 74, no. 8, pp. 4557–4565, 2006. View at Publisher · View at Google Scholar · View at PubMed
50. H. Nókleby, P. Aavitsland, J. O'Hallahan, B. Feiring, S. Tilman, and P. Oster, “Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease,” Vaccine, vol. 25, no. 16, pp. 3080–3084, 2007. View at Publisher · View at Google Scholar · View at PubMed
51. M.-C. Demachy, V. Vernet-Garnier, J. Cottin, et al., “Antimicrobial resistance data on 16,756 Streptococcus pneumoniae isolates in 1999: a pan-regional multicenter surveillance study in France,” Microbial Drug Resistance, vol. 11, no. 4, pp. 323–329, 2005. View at Publisher · View at Google Scholar · View at PubMed
52. G. B. Lesinski and M. A. Westerink, “Vaccines against polysaccharide antigens,” Current Drug Targets—Infectious Disorders, vol. 1, no. 3, pp. 325–334, 2001.
53. “Pneumococcal conjugate vaccine for childhood immunization—WHO position paper,” Weekly Epidemiological Record, vol. 82, no. 12, pp. 93–104, 2007.
54. “Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children,” April 2008, http://www.clinicaltrials.gov/.
55. “Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine,” April 2008, http://www.clinicaltrials.gov/.
56. S. Black, H. Shinefield, B. Fireman, et al., “Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children,” Pediatric Infectious Disease Journal, vol. 19, no. 3, pp. 187–195, 2000. View at Publisher · View at Google Scholar
57. C. G. Grijalva, J. P. Nuorti, P. G. Arbogast, S. W. Martin, K. M. Edwards, and M. R. Griffin, “Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis,” The Lancet, vol. 369, no. 9568, pp. 1179–1186, 2007. View at Publisher · View at Google Scholar · View at PubMed
58. C. J. Tsai, M. R. Griffin, J. P. Nuorti, and C. G. Grijalva, “Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States,” Clinical Infectious Diseases, vol. 46, no. 11, pp. 1664–1672, 2008. View at Publisher · View at Google Scholar · View at PubMed
59. J. Eskola, T. Kilpi, A. Palmu, et al., “Efficacy of a pneumococcal conjugate vaccine against acute otitis media,” The New England Journal of Medicine, vol. 344, no. 6, pp. 403–409, 2001. View at Publisher · View at Google Scholar · View at PubMed
60. F. Michon, C. Uitz, A. Sarkar, et al., “Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity,” Clinical and Vaccine Immunology, vol. 13, no. 8, pp. 936–943, 2006. View at Publisher · View at Google Scholar · View at PubMed
61. F. Y. C. Lin, V. A. Ho, H. B. Khiem, et al., “The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children,” The New England Journal of Medicine, vol. 344, no. 17, pp. 1263–1269, 2001. View at Publisher · View at Google Scholar
62. S. J. Cryz, Jr., J. O. Que, A. S. Cross, and E. Fürer, “Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine,” Vaccine, vol. 13, no. 5, pp. 449–453, 1995. View at Publisher · View at Google Scholar
63. T. Tollersrud, L. Zernichow, S. R. Andersen, K. Kenny, and A. Lund, “Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle,” Vaccine, vol. 19, no. 28-29, pp. 3896–3903, 2001. View at Publisher · View at Google Scholar
64. R. J. Singleton, T. W. Hennessy, L. R. Bulkow, et al., “Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage,” The Journal of the American Medical Association, vol. 297, no. 16, pp. 1784–1792, 2007. View at Publisher · View at Google Scholar · View at PubMed
65. J. Eskola, H. Peltola, and A. K. Takala, “Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy,” The New England Journal of Medicine, vol. 317, no. 12, pp. 717–722, 1987.
66. D. F. Kelly, E. R. Moxon, and A. J. Pollard, “Haemophilus influenzae type b conjugate vaccines,” Immunology, vol. 113, no. 2, pp. 163–174, 2004. View at Publisher · View at Google Scholar · View at PubMed
67. C. L. Yeh, D. F. Kelly, L.-M. Yu, et al., “Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody,” Clinical Infectious Diseases, vol. 46, no. 2, pp. 186–192, 2008. View at Publisher · View at Google Scholar · View at PubMed
68. J. McVernon, N. Andrews, M. P. E. Slack, and M. E. Ramsay, “Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis,” The Lancet, vol. 361, no. 9368, pp. 1521–1523, 2003. View at Publisher · View at Google Scholar
69. N. R. E. Kitchin, J. Southern, R. Morris, et al., “Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age,” Archives of Disease in Childhood, vol. 92, no. 1, pp. 11–16, 2007. View at Publisher · View at Google Scholar · View at PubMed
70. H.-J. Schmitt, G. Maechler, P. Habermehl, et al., “Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine,” Clinical and Vaccine Immunology, vol. 14, no. 4, pp. 426–434, 2007. View at Publisher · View at Google Scholar · View at PubMed
71. S. Gatchalian, E. Palestroque, I. De Vleeschauwer, et al., “The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components,” International Journal of Infectious Diseases, vol. 12, no. 3, pp. 278–288, 2008. View at Publisher · View at Google Scholar · View at PubMed
72. E. Vidor, A. Hoffenbach, and M. A. Fletcher, “Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses,” Current Medical Research and Opinion, vol. 17, no. 3, pp. 197–209, 2001. View at Publisher · View at Google Scholar
73. F. A. Wyle, M. S. Artenstein, B. L. Brandt, et al., “Immunologic response of man to group B meningococcal polysaccharide vaccines,” The Journal of Infectious Diseases, vol. 126, no. 5, pp. 514–521, 1972.
74. S. J. N. Devi, W. D. Zollinger, P. J. Snoy, et al., “Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys,” Infection and Immunity, vol. 65, no. 3, pp. 1045–1052, 1997.
75. C. Auckland, S. Gray, R. Borrow, et al., “Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom,” The Journal of Infectious Diseases, vol. 194, no. 12, pp. 1745–1752, 2006. View at Publisher · View at Google Scholar · View at PubMed
76. G. Blanchard Rohner, M. D. Snape, D. F. Kelly, et al., “The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response,” The Journal of Immunology, vol. 180, no. 4, pp. 2165–2173, 2008.
77. I. Tichmann-Schumann, P. Soemantri, U. Behre, et al., “Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine,” Pediatric Infectious Disease Journal, vol. 24, no. 1, pp. 70–77, 2005. View at Publisher · View at Google Scholar
78. M. H. Kyaw, R. Lynfield, W. Schaffner, et al., “Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae,” The New England Journal of Medicine, vol. 354, no. 14, pp. 1455–1463, 2006. View at Publisher · View at Google Scholar · View at PubMed
79. R. Veenhoven, D. Bogaert, C. Uiterwaal, et al., “Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study,” The Lancet, vol. 361, no. 9376, pp. 2189–2195, 2003. View at Publisher · View at Google Scholar · View at PubMed
80. J. Bernatoniene and A. Finn, “Advances in pneumococcal vaccines advantages for infants and children,” Drugs, vol. 65, no. 2, pp. 229–255, 2005. View at Publisher · View at Google Scholar
81. T. Nieminen, J. Eskola, and H. Käyhty, “Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum,” Vaccine, vol. 16, no. 6, pp. 630–636, 1998. View at Publisher · View at Google Scholar
82. A. Nurkka, H. Ahman, M. Korkeila, V. Jantti, H. Käyhty, and J. Eskola, “Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine,” Pediatric Infectious Disease Journal, vol. 20, no. 1, pp. 25–33, 2001. View at Publisher · View at Google Scholar
83. A. Marchant and M. Newport, “Prevention of infectious disease by neonatal and early infantile immunization: prospects for the new millennium,” Current Opinion in Infectious Diseases, vol. 13, no. 3, pp. 241–246, 2000.
84. N. Cohen, M. Stolarsky-Bennun, H. Amir-Kroll, et al., “Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive,” The Journal of Immunology, vol. 180, no. 4, pp. 2409–2418, 2008.
85. O. Levy, E. E. Suter, R. L. Miller, and M. R. Wessels, “Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells,” Blood, vol. 108, no. 4, pp. 1284–1290, 2006. View at Publisher · View at Google Scholar · View at PubMed
86. R. S. Chu, T. Mccool, N. S. Greenspan, J. R. Schreiber, and C. V. Harding, “CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies,” Infection and Immunity, vol. 68, no. 3, pp. 1450–1456, 2000. View at Publisher · View at Google Scholar
87. S. Konen-Waisman, M. Fridkin, and I. R. Cohen, “Self and foreign 60-kilodalton heat shock protein T cell epitope peptides serve as immunogenic carriers for a T cell-independent sugar antigen,” The Journal of Immunology, vol. 154, no. 11, pp. 5977–5985, 1995.
88. H. Amir-Kroll, L. Riveron, M. E. Sarmiento, G. Sierra, A. Acosta, and I. R. Cohen, “A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide,” Vaccine, vol. 24, no. 42-43, pp. 6555–6563, 2006. View at Publisher · View at Google Scholar · View at PubMed
89. H. Jakobsen, S. Bjarnarson, G. Del Giudice, M. Moreau, C.-A. Siegrist, and I. Jonsdottir, “Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice,” Infection and Immunity, vol. 70, no. 3, pp. 1443–1452, 2002. View at Publisher · View at Google Scholar
90. B. C. Baudner, J. C. Verhoef, M. M. Giuliani, et al., “Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform,” Journal of Drug Targeting, vol. 13, no. 8-9, pp. 489–498, 2005. View at Publisher · View at Google Scholar · View at PubMed
91. A. Sabirov and D. W. Metzger, “Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media,” Vaccine, vol. 24, no. 27-28, pp. 5584–5592, 2006. View at Publisher · View at Google Scholar · View at PubMed
92. M. T. De Magistris, “Mucosal delivery of vaccine antigens and its advantages in pediatrics,” Advanced Drug Delivery Reviews, vol. 58, no. 1, pp. 52–67, 2006. View at Publisher · View at Google Scholar · View at PubMed
93. S. Rapola, V. Jantti, R. Haikala, et al., “Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media,” The Journal of Infectious Diseases, vol. 182, no. 4, pp. 1146–1152, 2000. View at Publisher · View at Google Scholar
94. A. Virolainen, W. Russell, M. J. Crain, S. Rapola, H. Käyhty, and D. E. Briles, “Human antibodies to pneumococcal surface protein A in health and disease,” Pediatric Infectious Disease Journal, vol. 19, no. 2, pp. 134–138, 2000. View at Publisher · View at Google Scholar
95. K. E. Morrison, D. Lake, J. Crook, et al., “Confirmation of psaA in all 90 serotypes of Streptococcus pneumoniae by PCR and potential of this assay for identification and diagnosis,” Journal of Clinical Microbiology, vol. 38, no. 1, pp. 434–437, 2000.
96. M. C. Lawrence, P. A. Pilling, V. C. Epa, A. M. Berry, A. D. Ogunniyi, and J. C. Paton, “The crystal structure of pneumococcal surface antigen PsaA reveals a metal-binding site and a novel structure for a putative ABC-type binding protein,” Structure, vol. 6, no. 12, pp. 1553–1561, 1998. View at Publisher · View at Google Scholar
97. A. Weintraub, “Immunology of bacterial polysaccharide antigens,” Carbohydrate Research, vol. 338, no. 23, pp. 2539–2547, 2003. View at Publisher · View at Google Scholar
98. T. Kieber-Emmons, B. Monzavi-Karbassi, B. Wang, P. Luo, and D. B. Weiner, “Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response,” The Journal of Immunology, vol. 165, no. 2, pp. 623–627, 2000.